Skip to main content
. 2024 Nov 16;31(11):7244–7257. doi: 10.3390/curroncol31110534

Table 2.

Biomarker results.

Biomarker Result Patients Eligible, N (%)
FDA-approved therapy
Received Therapy
33 (21.8)
26 (17.2)
Targeted clinical trial
Enrolled in Trial
27 (17.9)
1 (0.7)
Off-label therapy 9 (6.0)
Received Therapy 2 (1.3)
Therapeutic resistance 20 (13.2)
Germline implications 15 (10.0)
None 64 (42.4)